U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook.

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 billion DKK ($11.9 billion). Net income for the quarter rose 14% to 29 billion DKK ($4.4 billion). According to S&P Global Market Intelligence data, that works out to $0.95 per share.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.